Cancer hospital, Fudan University

Shanghai 200032

0 studies enrolling now · 5 studies all time

What they study most

Advanced Solid Tumor, Breast Cancer Metastatic, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma

Studies at this site

• A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations — Completed
• DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer — Completed
• Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) — Completed
• Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma — Completed
• Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma — Completed